What happened
CKD Bio reported separate results for FY2025: revenue of US$112M (−6.8% year on year), operating profit of US$2.52M (−67.1% year on year) and a net loss of US$2.02M (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$112M |
|---|---|
| Revenue vs a year earlier | −6.8% |
| Operating profit | US$2.52M |
| Net income | −US$2.02M |
| Period | FY2025 (separate) |
| Filed | 2026-01-30, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260130801091 → open original filing |
Source: DART. Information only, not investment advice.